

LUNG CANCER

An International Journal for Lung Cancer and other
Thoracic Malignancies

EDITOR-IN CHIEF: Rolf Stahel
Zurich, Switzerland



ABSTRACTED/INDEXED IN: Current Contents/Clinical Medicine; Excerpta Medica (EMBASE); Index Medicus (MEDLINE); Oncology Information Service; SciSearch; Current Awareness in Biological Services (CABS)

IMPACT FACTOR/RANKING: 3.172 49/123 Oncology
9/33 Respiratory System

SCOPE: Lung Cancer aims to provide individuals or organisations with the most recent information on lung cancer. The Journal publishes full-length articles of original research on clinical and basic science aspects of topics represented by the fields of interest of Lung Cancer (prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities).

TARGET AUDIENCE: Clinical Oncologists, Internists, Radiologists, Radiotherapists, Thoracic Surgeons, Pulmonary Disease Physicians, Pathologists, Epidemiologists, Public Health Specialists

FREQUENCY: 12 issues p/y

CIRCULATION: 250

GEOGRAPHICAL DISTRIBUTION: Europe: 52%
USA/Canada: 14%
Asia: 29%
ROW: 5%

ELECTRONIC CIRCULATION: 21130 Electronic Circulation: Science Direct FTA Average download per month July 05-June 06 www.sciencedirect.com

WEBSITE: <http://www.lungcancerjournal.info/>

SUPPLEMENT PUBLISHING LEAD TIME: From Submission to Acceptance: approximately 4 weeks
From Acceptance to Publication: approximately 14 weeks
Fast Track publication within 8 weeks is available on request

GUIDE FOR AUTHORS: www.elsevier.com/authors

Gemma Schaepman, Senior Account Manager
C.I.P. – Conference Information Publishing, P.O. Box 993, 1000 AZ Amsterdam, The Netherlands
Tel: (+31) 20 485 2930 Fax: (+31) 20 485 2940 E-mail: g.schaepman@elsevier.com
www.cip-elsevier.com